

## Summary

The Charles River ion channel portfolio includes over 120 targets which have been organized into Channel Panels<sup>®</sup> based on current scientific findings, proving a useful tool in guiding early screening and selectivity profiling.



DISCOVERY

 Click to learn more

### Ion Channel Families:

- Calcium, voltage-gated (Cav1.2/ $\beta_2/\alpha_2\delta_1$ , Cav1.3/ $\beta_3/\alpha_2\delta_1$  and Cav3.2)
- Exchanger (NCX1.1)
- Hyperpolarization-gated (HCN2 and HCN4)
- Ligand-gated (nAChR $\alpha_7$  and P2X4)
- Potassium, voltage-gated (Kv1.3, Kv1.5, Kv4.3, KvLQT1/mink (Kv7.1) and hERG (Kv11.1))
- Potassium, inward rectifier (Kir2.1, Kir3.1/3.4 and Kir6.2/SUR2A)
- Potassium, calcium-activated (BK, IK and SK3)
- Sodium, epithelial (ENaC)
- Sodium, voltage-gated (Nav1.5)
- Transient receptor potential (TRPC1, TRPC4, TRPC6, TRPM4, TRPV1 and TRPV4)

## Ion Channel Selectivity Profiling: Cardiovascular

Our Cardiovascular Channel Panel<sup>®</sup> includes ion channels which regulate blood flow primarily by vasodilation and constriction of blood vessels.

### Selectivity Profiling

Identification of a compound's target specificity and potential for off-target effects is a critical step in the drug discovery process and often includes assessments against specific target class families, critical safety targets or by therapeutic area. In addition to our [therapeutic area-specific Channel Panels<sup>®</sup>](#), we offer screening on a number of [electrophysiology platforms](#). When required, our scientists can design customized panels to meet a client's needs. As pioneers in the field of ion channels, we are able to provide expert consultation to facilitate interpretation of results.

### Ion Channels and Vasodilation

Physiological regulation of vascular resistance relies on the control of Ca<sup>2+</sup>-dependent contraction of the smooth muscle that surrounds the endothelial cell lining of the vessel lumen. Control of smooth muscle tension involves a variety of Ca<sup>2+</sup>-permeable channels (e.g., Cav1.2, P2X4, nAChR $\alpha_7$  and most TRP channels), as well as channels that regulate release of vasoactive substances, and channels that regulate arterial tone via control of membrane potential (K<sup>+</sup>-selective channels BK, SK3, IK, Kir2.1, Kir6.1, Kir6.2, Kv1.5 and Kv7.1; and a non-selective channel TRPM4). Under pathological conditions (e.g., vascular inflammation, chronic hypertension, heart failure or hypoxia) decreased vascular integrity, increased endothelial permeability, and hyperplasia may compromise vascular function. [Ion channels](#) involved in pathological mechanisms include Kv7.1, nAChR $\alpha_7$  and several [TRP channels](#). Thus, the [Cardiovascular Channel Panel<sup>®</sup>](#) represents a selection of channels that are potential therapeutic targets for conditions such as hypertension, atherosclerosis, and heart failure. Moreover, drug-induced channel dysfunction may be responsible for adverse effects.

Need a custom version of this assay? Visit [criver.com/pi-ds-ion-channel-profiling-assay](https://www.criver.com/pi-ds-ion-channel-profiling-assay)

EVERY STEP OF THE WAY